Anzeige
Mehr »
Login
Freitag, 30.07.2021 Börsentäglich über 12.000 News von 667 internationalen Medien
InnoCan Pharma mit dem heiligen Gral im Milliarden-Dollar-Teich!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
122 Leser
Artikel bewerten:
(0)

DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 5,2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ: AKTX) for possible violations of federal securities laws from March 30, 2017 through May 11, 2017 inclusive (the "Class Period"). Investors who purchased or otherwise acquired Akari shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.

According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called "Akari's Coversin matches Soliris in Phase II." The next day it was announced that the report was withdrawn because of "material inaccuracies." On May 11, 2017, Akari announced that Chief Executive Officer Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. Upon the release of this information, Akari shares fell in value, which harmed investors according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2017 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.